Sinopharm Group Co. Ltd. (SHTDY)
USD 13.79
(0.0%)
USD 13.79
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 9.05 Billion CNY | 6.19% |
| 2022 | 8.52 Billion CNY | 9.89% |
| 2021 | 7.75 Billion CNY | 7.95% |
| 2020 | 7.18 Billion CNY | 14.95% |
| 2019 | 6.25 Billion CNY | 7.14% |
| 2018 | 5.83 Billion CNY | 10.46% |
| 2017 | 5.28 Billion CNY | 13.68% |
| 2016 | 4.64 Billion CNY | 23.58% |
| 2015 | 3.76 Billion CNY | 30.81% |
| 2014 | 2.87 Billion CNY | 27.77% |
| 2013 | 2.25 Billion CNY | 13.99% |
| 2012 | 1.97 Billion CNY | 26.48% |
| 2011 | 1.56 Billion CNY | 29.11% |
| 2010 | 1.2 Billion CNY | 42.91% |
| 2009 | 845.81 Million CNY | 3.39% |
| 2008 | 818.1 Million CNY | 52.65% |
| 2007 | 535.94 Million CNY | 193.75% |
| 2006 | 182.44 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.42 Billion CNY | -51.98% |
| 2024 Q2 | 2.28 Billion CNY | 60.81% |
| 2023 Q3 | 1.99 Billion CNY | -20.77% |
| 2023 FY | 9.05 Billion CNY | 6.19% |
| 2023 Q1 | 1.59 Billion CNY | -40.41% |
| 2023 Q4 | 2.95 Billion CNY | 48.48% |
| 2023 Q2 | 2.51 Billion CNY | 58.09% |
| 2022 Q4 | 2.66 Billion CNY | 23.37% |
| 2022 Q1 | 1.42 Billion CNY | -30.6% |
| 2022 FY | 8.52 Billion CNY | 9.89% |
| 2022 Q2 | 2.26 Billion CNY | 58.69% |
| 2022 Q3 | 2.16 Billion CNY | -4.53% |
| 2021 FY | 7.75 Billion CNY | 7.95% |
| 2021 Q3 | 2.11 Billion CNY | -10.49% |
| 2021 Q2 | 2.36 Billion CNY | 94.61% |
| 2021 Q4 | 2.05 Billion CNY | -2.88% |
| 2021 Q1 | 1.21 Billion CNY | -45.43% |
| 2020 Q2 | 2.08 Billion CNY | 156.6% |
| 2020 Q4 | 2.22 Billion CNY | 8.04% |
| 2020 Q3 | 2.06 Billion CNY | -1.0% |
| 2020 Q1 | 812.02 Million CNY | -50.97% |
| 2020 FY | 7.18 Billion CNY | 14.95% |
| 2019 Q3 | 1.62 Billion CNY | -11.24% |
| 2019 FY | 6.25 Billion CNY | 7.14% |
| 2019 Q1 | 1.14 Billion CNY | -33.28% |
| 2019 Q2 | 1.82 Billion CNY | 59.64% |
| 2019 Q4 | 1.65 Billion CNY | 2.08% |
| 2018 Q2 | 1.9 Billion CNY | 113.45% |
| 2018 FY | 5.83 Billion CNY | 10.46% |
| 2018 Q1 | 891.55 Million CNY | -36.57% |
| 2018 Q3 | 1.32 Billion CNY | -30.49% |
| 2018 Q4 | 1.71 Billion CNY | 29.75% |
| 2017 FY | 5.28 Billion CNY | 13.68% |
| 2017 Q3 | 1.4 Billion CNY | 1.8% |
| 2017 Q4 | 1.4 Billion CNY | 0.0% |
| 2017 Q1 | 1.38 Billion CNY | 31.51% |
| 2017 Q2 | 1.38 Billion CNY | 0.0% |
| 2016 Q1 | 1.01 Billion CNY | 9.75% |
| 2016 Q4 | 1.04 Billion CNY | 0.0% |
| 2016 Q3 | 1.04 Billion CNY | -30.74% |
| 2016 Q2 | 1.51 Billion CNY | 48.64% |
| 2016 FY | 4.64 Billion CNY | 23.58% |
| 2015 Q2 | 1.01 Billion CNY | 13.81% |
| 2015 Q3 | 929.18 Million CNY | -8.79% |
| 2015 Q4 | 929.18 Million CNY | 0.0% |
| 2015 FY | 3.76 Billion CNY | 30.81% |
| 2015 Q1 | 895.11 Million CNY | 27.02% |
| 2014 FY | 2.87 Billion CNY | 27.77% |
| 2014 Q4 | 704.68 Million CNY | 0.0% |
| 2014 Q3 | 704.68 Million CNY | -3.83% |
| 2014 Q2 | 732.73 Million CNY | 0.0% |
| 2014 Q1 | 732.73 Million CNY | 33.43% |
| 2013 Q1 | 575.86 Million CNY | 0.0% |
| 2013 FY | 2.25 Billion CNY | 13.99% |
| 2013 Q2 | 575.86 Million CNY | 0.0% |
| 2013 Q4 | 549.13 Million CNY | 0.0% |
| 2013 Q3 | 549.13 Million CNY | -4.64% |
| 2012 FY | 1.97 Billion CNY | 26.48% |
| 2011 FY | 1.56 Billion CNY | 29.11% |
| 2010 FY | 1.2 Billion CNY | 42.91% |
| 2009 FY | 845.81 Million CNY | 3.39% |
| 2008 FY | 818.1 Million CNY | 52.65% |
| 2007 FY | 535.94 Million CNY | 193.75% |
| 2006 FY | 182.44 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| China Medicine Corporation | 1.71 Million USD | -526993.278% |
| DH Enchantment Inc. | -156.15 Thousand USD | 5798105.802% |
| Exlites Holdings International, Inc. | -90.49 Thousand USD | 10005028.558% |
| Itonis, Inc. | -38.31 Thousand USD | 23631139.073% |
| One Step Vending Corp. | -27.79 Thousand USD | 32579301.151% |
| MediPal Holdings Corporation | 274.02 Million USD | -3203.987% |
| PD-Rx Pharmaceuticals, Inc. | -98.06 Thousand USD | 9232601.224% |
| Pharmagen, Inc. | -6457.61 USD | 140203054.344% |
| Suzuken Co., Ltd. | 191.71 Billion USD | 95.277% |